Methylphenidate News and Research

RSS

ADHD medication proves most effective in treating symptoms, new study finds

A comprehensive overview of treatment options available for ADHD for children and adolescent individuals.

27 Mar 2024

Study reveals ADHD medication reduces psychiatric hospitalizations and work disability

Study highlights the benefits and potential risks of ADHD medication, revealing that stimulants like amphetamines and methylphenidate reduce the risk of psychiatric hospitalization and improve long-term employment outcomes, though concerns about adverse effects such as increased heart rate and potential for triggering psychosis or mania remain.

24 Mar 2024

Understanding giggle incontinence: Causes, symptoms, and management

Giggle incontinence, a unique form of laughter-induced urinary incontinence, primarily affects children without other urological disorders, with treatment options including urotherapy, biofeedback, and methylphenidate.

27 Feb 2024

Study reveals G6PD deficiency linked to higher ADHD risk and increased use of stimulant medications

The risk of Attention Deficit/Hyperactivity Disorder (ADHD) among glucose 6-phosphate dehydrogenase (G6PD)-deficient individuals.

1 Dec 2023

Experts shed light on how autism affects the diagnosis, treatment of epilepsy and vice versa

Compared with the general population, epilepsy is more common in people with autism-;and autism is more common in people with epilepsy. How can autism affect the diagnosis and treatment of epilepsy, and vice versa? Joy Mazur spoke to Dr. Colin Reilly and Dr. Stéphane Auvin.

17 Nov 2023

New research explores the unique effects of ADHD medications on Drosophila brain cells

The effect of two drugs used for the treatment of attention-deficit/hyperactivity disorder.

15 Nov 2023

Neural circuits respond to rapid dopamine surges

Researchers assess the pharmacodynamics of dopamine signaling, brain connectivity/activity, and self-documented 'high' following methylphenidate exposure.v

14 Nov 2023

Doctors need better guidance on treating ADHD in over 50s

Doctors urgently need better international guidance on treating attention deficit hyperactivity disorder (ADHD) in the over 50s, conclude world-leading experts reviewing current research on this increasing issue globally.

20 Sep 2023

ADHD drug could serve as a cocaine-replacement therapy

Cocaine use continues to be a public health problem, yet despite concerted efforts, no drugs have been approved to resolve cocaine addiction. Research suggests that the attention-deficit/hyperactivity disorder drug methylphenidate (MPH; Ritalin) could serve as a cocaine-replacement therapy, but clinical results have been mixed.

30 Aug 2023

Smart drugs fall short as cognitive function enhancers

A recent Science Advances study investigated the effectiveness of three popular smart drugs, namely, modafinil (MOD), methylphenidate (MPH), and dextroamphetamine (DEX), against the difficulty of real-life daily tasks, i.e., the 0-1 knapsack optimization problem (“knapsack task”). A knapsack task is basically a combinatorial optimization task, the class of NP-time challenging problems.

18 Jun 2023

Researchers gain new insights into ADHD drug's mechanism of action

For decades, doctors have treated kids with attention-deficit/hyperactivity disorder (ADHD) with methylphenidate, a stimulant drug sold as Ritalin and Concerta, making it one of the most widely prescribed medications aimed at the central nervous system.

8 Dec 2022

Noradrenergic drugs could be repurposed to offer effective treatment for Alzheimer's disease symptoms

There is "good evidence" that drugs to treat attention deficit hyperactivity disorder (ADHD) might also successfully treat key aspects of Alzheimer's disease, finds a pooled data analysis of the available research, published online in the Journal of Neurology Neurosurgery & Psychiatry.

6 Jul 2022

Caffeine could be a therapeutic arsenal to alleviate some of the ADHD symptoms

Attention Deficit Hyperactivity Disorder, or ADHD, is a psychiatric pathology for which diagnosis has increased exponentially over the last 20 years.

29 Mar 2022

Study examines the effects of methylphenidate on mental fatigue in multiple sclerosis patients

A team of researchers at Kessler Foundation studied the effects of methylphenidate on mental fatigue in individuals with multiple sclerosis (MS). This is the first study to examine the psychostimulant's effects on 'state' vs 'trait' mental fatigue in MS.

18 Dec 2021

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Leading Producer of Controlled Substance APIs Now Supplying Lisdex API to Generic Drug Manufacturers Preparing for the 2023 Patent Expiry of Top-Selling Branded ADHD Therapy.

3 Dec 2021

Study reveals potential therapeutic target to tackle ADHD and impulsivity

A study published in the journal Pharmacological Research describes the existence of a complex built by dopamine and noradrenergic receptors that could be a therapeutic target of potential interest to tackle the attention deficit hyperactivity disorder (ADHD) and impulsivity.

23 Sep 2021

ADHD medications may lower suicide risk in children with hyperactivity, behavioral disorders

ADHD medications may lower suicide risk in children with hyperactivity, oppositional defiance and other behavioral disorders, according to new research from the Lifespan Brain Institute (LiBI) of Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania.

7 Jun 2021

ADHD medications may decrease suicidality risk in certain children

ADHD medications may lower suicide risk in children with hyperactivity, oppositional defiance and other behavioral disorders, according to new research from the Lifespan Brain Institute of Children's Hospital of Philadelphia and the University of Pennsylvania.

5 Jun 2021

Researchers discover new brain circuit that may help fight obesity

Like a good story, feeding has a beginning, a middle and an end. It begins with appetite prompting the search for food, continues with eating the food and it ends when satiation hits and the consumption of food is stopped.

27 May 2021

Study analyzes two different classes of drugs in a large group of preschoolers with ADHD

In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children.

5 May 2021